Clinical and immunological characteristics of chronic obstructive pulmonary disease with frequent exacerbations associated with obliterating atherosclerosis of lower limb arteries

Chronic obstructive pulmonary disease (COPD) is often associated with atherosclerotic cardiovascular disease (ASCVD), of which obliterating atherosclerosis of lower limb arteries or peripheral arterial disease (PAD) is an important component. The aim of the study was to evaluate the clinical, functional and immunological characteristics of COPD with the phenotype of frequent exacerbations in combination with PAD. Materials and methods. Four groups of COPD patients were included: 20 COPD patients with infrequent exacerbations without ASCVD, 20 COPD patients with frequent exacerbations without ASCVD, 20 patients with frequent exacerbations and PAD, and 20 COPD patients with a phenotype of frequent exacerbations and PAD. Data from 20 healthy controls were analysed for comparison. Clinical and spirometric data were evaluated. General clinical laboratory data and immunological markers (interleukin 1 beta (IL1b) and tumor necrosis factor (TNF) in exhaled breath condensate (EBC) and serum were analysed. Results. Higher levels of IL1b and TNF in EBC and serum were found in patients with COPD and PAD compared to COPD patients without ASCVD (p<0.05) and healthy controls (p<0.001). The high prevalence of COPD exacerbates the clinical and immunological characteristics of disease severity both without ASCVD and with concomitant PAD. Conclusions. COPD with the phenotype of frequent exacerbations and PAD is characterized by greater severity of local and systemic inflammation, which corresponds to increased inflammatory markers in EBC and serum.

1. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9.

2. Park SC, Kim DW, Park EC, Shin CS, Rhee CK, Kang YA, Kim YS. Mortality of patients with chronic obstructive pulmonary disease: a nationwide populationbased cohort study. Korean J Intern Med. 2019 Nov;34(6):1272-1278. doi: 10.3904/kjim.2017.428.

3. Kotaki K, Ikeda H, Fukuda T, et al. Trends in the prevalence of COPD in elderly individuals in an air-polluted city in Japan: a cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2019 Apr 3;14:791-798. doi: 10.2147/COPD.S189372.

4. Калинин Р.Е., Сучков И.А., Чобанян А.А., и др. Генетические предик- торы неблагоприятного течения облитерирующего атеросклероза ар- терий нижних конечностей. Российский медико-биологический вестник имени академика И.П. Павлова. 2021;29(2):251-256. [Kalinin RE, Suchkov IA, Chobanyan AA, et al. Genetic predictors of an unfavorable course of obliterating atherosclerosis of lower limb arteries. I.P. Pavlov Russian Medical Biological Herald. 22021;29(2):251-256. (In Russ.)]. doi: 10.17816/PAVLOVJ65383

5. Калинин Р.Е., Сучков И.А., Чобанян А.А. Перспективы прогнозиро- вания течения облитерирующего атеросклероза артерий нижних конеч- ностей. Наука молодых (Eruditio Juvenium). 2019;7(2):274-82. [Kalinin RE, Suchkov IA, Chobanyan AA. Prospects for forecasting the course of obliterating atherosclerosis of lower limb arteries. Science of the young (Eruditio Juvenium). 2019;7(2):274-82. (In Russ.)]. doi:10.23888/HMJ201972274-282

6. Brassington K, Selemidis S, Bozinovski S, Vlahos R. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. Clin Sci (Lond). 2022 Mar 31;136(6):405-423. doi: 10.1042/CS20210835.

7. Kotlyarov S. Analysis of differentially expressed genes and signaling pathways involved in atherosclerosis and chronic obstructive pulmonary disease. Biomol Concepts. 2022 Feb 21;13(1):34-54. doi: 10.1515/bmc-2022-0001.

8. Søyseth V, Kononova N, Neukamm A, et al. Systemic inflammation induced by exacerbation of COPD or pneumonia in patients with COPD induces cardiac troponin elevation. BMJ Open Respir Res. 2021 Aug;8(1):e000997. doi: 10.1136/bmjresp-2021-000997.

9. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013 Jun 12;309(22):2353-61. doi: 10.1001/jama.2013.5732.

10. Pecci R, De La Fuente Aguado J, et al. Peripheral arterial disease in patients with chronic obstructive pulmonary disease. Int Angiol. 2012 Oct;31(5):444-53.

11. Terzikhan N, Lahousse L, Verhamme KMC, et al. COPD is associated with an increased risk of peripheral artery disease and mortality. ERJ Open Res. 2018 Dec 21;4(4):00086-2018. doi: 10.1183/23120541.00086-2018.

12. Liao KM, Kuo LT, Lu HY. Increased risk of peripheral arterial occlusive diseases in patients with chronic obstructive pulmonary disease: a nationwide study in Taiwan. Int J Chron Obstruct Pulmon Dis. 2019 Jul 4;14:1455-1464. doi: 10.2147/COPD.S202029.

13. Barrecheguren M, Miravitlles M. COPD heterogeneity: implications for management. Multidiscip Respir Med. 2016 Mar 17;11:14. doi: 10.1186/s40248-016-0053-4.

14. Ghelli F, Panizzolo M, Garzaro G, et al. Inflammatory Biomarkers in Exhaled Breath Condensate: A Systematic Review. Int J Mol Sci. 2022 Aug 29;23(17):9820. doi: 10.3390/ijms23179820.

15. Tousoulis D, Oikonomou E, Economou EK, et al. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016 Jun 7;37(22):1723-32. doi: 10.1093/eurheartj/ehv759.